Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Anna A Mosikian"'
Publikováno v:
Future Science OA, Vol 8, Iss 3 (2022)
Background: The effects of liraglutide on body weight and hemoglobin A1C (HbA1c) level vary greatly. The cost of this drug negatively affects treatment adherence. Aim: To reveal the baseline patient characteristics, associated with a better response
Externí odkaz:
https://doaj.org/article/0381052c0e684e96aa77752c9cf96234
Autor:
Nataliya S. Novoselova, Anna A. Mosikian, Olga Y. Martyanova, Evgenya M. Patrakeeva, Alsu G. Zalevskaya
Publikováno v:
Сахарный диабет, Vol 21, Iss 6, Pp 472-479 (2018)
Background: Only a little percent of chronically ill patients was found to follow physicians’ prescriptions. One of the reasons for this issue is misunderstanding of recommendations due to inappropriate interpretation of medical terms, contained in
Externí odkaz:
https://doaj.org/article/e2b806c8604a4e359177949b3b2458fe
Autor:
Anna A. Mosikian, Alina Y. Babenko, Yulia A. Sevastyanova, Roman V. Drai, Evgenij V. Shlyakhto
Publikováno v:
Сахарный диабет, Vol 21, Iss 5, Pp 333-343 (2018)
Background: Individualized treatment has already become a part of a routine clinical care. Many data on the effectiveness prediction of commercially available DPP-4 inhibitors had been published, but not on the effectiveness prediction of evogliptin.
Externí odkaz:
https://doaj.org/article/0cda49c2db13461287d49fbf760d288a
Autor:
Alina Y. Babenko, Anna A. Mosikian, Igor E. Makarenko, Victoriya V. Leusheva, Evgeny V. Shlyakhto
Publikováno v:
Сахарный диабет, Vol 21, Iss 4, Pp 241-254 (2018)
Background: Dipeptidyl-peptidase-4 inhibitors (iDPP-4) are pathogenically targeted drugs for diabetes mellitus type 2 (T2DM). Evogliptin is a new member of iDPP-4 class. The drug has the longest half-elimination period among the class, and its effica
Externí odkaz:
https://doaj.org/article/27831b07e20444e996454c54095fada3
Autor:
Maria V Verbovaya, Ivan S Lunev, Anna A Mosikian, Bella R Zinnatulina, Alexandr Y Mayorov, Diana N Alpenidze, Igor E. Makarenko, Roman V. Drai, Alexander L Khokhlov, Valeria L Orlova
Publikováno v:
Journal of Comparative Effectiveness Research. 10:55-66
Aim: To compare safety (immunogenicity) and efficacy of a biosimilar insulin GP-Lis25 and a reference insulin Ly-Lis25 (Humalog Mix 25) in Type 2 diabetes mellitus (T2D) patients. Materials & methods: This randomized open-label, 26-week clinical tria
Autor:
Svetlana T Zyangirova, Tatiana L Karonova, Tatiana M Belikova, Alexander L Khokhlov, Roman V. Drai, Alexander Yur'evich Mayorov, Igor E. Makarenko, Anna A Mosikian, Alsu Gafurovna Zalevskaya, Olena A Afonkina
Publikováno v:
Journal of Comparative Effectiveness Research. 9:263-273
Aim: To compare safety (immunogenicity) and efficacy of GP40061 insulin glargine (GP-Gla) and Lantus ® (Sanofi glargine, Sa-Gla) in people with diabetes mellitus. Materials & methods: This randomized open-label, 26-week clinical trial enrolled 180 T
Autor:
Tatiana L, Karonova, Alexander Y, Mayorov, Maxim A, Magruk, Svetlana T, Zyangirova, Irina V, Grigoryeva, Oleg K, Khmelnitski, Anton, Myshkovets, Tatyana M, Parfenova, Anna A, Mosikian, Roman V, Drai
Publikováno v:
Journal of comparative effectiveness research. 10(9)
Autor:
Anna A Mosikian, Nataliya S. Novoselova, Olga Yuryevna Martyanova, Evgenya M. Patrakeeva, Alsu Gafurovna Zalevskaya
Publikováno v:
Сахарный диабет, Vol 21, Iss 6, Pp 472-479 (2018)
Background: Only a little percent of chronically ill patients was found to follow physicians’ prescriptions. One of the reasons for this issue is misunderstanding of recommendations due to inappropriate interpretation of medical terms, contained in
Publikováno v:
Journal of Comparative Effectiveness Research. 8:113-120
Aim: To identify correlations between quality of life (QoL), emotional and mental state in patients with Type 2 diabetes mellitus (T2DM) and to evaluate its contribution in prediction of compliance. Materials & methods: The T2DM patients aged 18–75
Publikováno v:
Сахарный диабет, Vol 21, Iss 5, Pp 333-343 (2018)
Background: Individualized treatment has already become a part of a routine clinical care. Many data on the effectiveness prediction of commercially available DPP-4 inhibitors had been published, but not on the effectiveness prediction of evogliptin.